You are here

Adding Pioglitazone Could Improve Molecular Response in CML Patients

Article type:

Original publication date: 
Sunday, January 8, 2017

News, January 04, 2017

 

Residual CML disease remains detectable above the level of MR4.5 in 40% to 90% of patients in spite of sustained imatinib therapy,” wrote study authors led by Philippe Rousselot, MD, PhD, of Hôpital André Mignot in Le Chesnay, France. Recent preclinical work has shown that PPAR-γ agonists such as pioglitazone can erode the CML leukaemia stem cell pool, potentially sensitising quiescent CML stem cells to imatinib.

Read more